Literature DB >> 18272203

Influence of the TP53 codon 72 polymorphism on the cellular responses to X-irradiation in fibroblasts from nonagenarians.

P Martijn den Reijer1, Andrea B Maier, Rudi G J Westendorp, Diana van Heemst.   

Abstract

In mice, genetic modification of the gene encoding p53 affects both cancer incidence and longevity. In humans, we recently found that a TP53 codon 72 Arginine (Arg) to Proline (Pro) polymorphism affected both cancer incidence and longevity as well. The TP53 codon 72 polymorphism has previously been shown to influence the apoptotic potential of human cells in response to oxidative stress. Here, we studied the influence of this polymorphism on the cellular responses to X-irradiation of fibroblasts obtained from nonagenarians. We found that the average clonogenic survival after X-irradiation was similar for the three TP53 codon 72 genotype groups. As described before, X-irradiation did not induce an appreciable degree of apoptosis in human fibroblasts. However, percentages of senescence-associated (SA)-beta-galactosidase positive cells (p < 0.001), micronucleated cells (p < 0.001) and cells displaying abnormal nuclear morphologies (p < 0.001) significantly increased with the radiation dose. Compared to Arg/Arg fibroblasts, Pro/Pro fibroblasts exhibited higher irradiation dose-dependent increases in SA-beta-galactosidase positive cells (p(interaction) = 0.018), micronucleated cells (p(interaction) = 0.005) and cells displaying abnormal nuclear morphologies (p(interaction) = 0.029) at 3 days after irradiation. Possibly, these differences in cellular responses to stress between the TP53 codon 72 genotypes contribute to the differences in cancer incidence and longevity observed earlier for these genotypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18272203     DOI: 10.1016/j.mad.2007.12.006

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  7 in total

Review 1.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

2.  Role of senescence and mitotic catastrophe in cancer therapy.

Authors:  Richa Singh; Jasmine George; Yogeshwer Shukla
Journal:  Cell Div       Date:  2010-01-21       Impact factor: 5.130

3.  Association between polymorphisms in tumor suppressor genes and oncogenes and risk of hepatocellular carcinoma: a case-control study in an HCC epidemic area within the Han Chinese population.

Authors:  Chenghao Su; Yong Lin; Jianjun Niu; Lin Cai
Journal:  Med Oncol       Date:  2014-11-21       Impact factor: 3.064

4.  The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation.

Authors:  Amanda K Frank; Julia I-Ju Leu; Yan Zhou; Karthik Devarajan; Tatiana Nedelko; Andres Klein-Szanto; Monica Hollstein; Maureen E Murphy
Journal:  Mol Cell Biol       Date:  2011-01-18       Impact factor: 4.272

5.  CSF1 is a novel p53 target gene whose protein product functions in a feed-forward manner to suppress apoptosis and enhance p53-mediated growth arrest.

Authors:  Gregory Azzam; Xuting Wang; Douglas Bell; Maureen E Murphy
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

6.  The p53 codon 72 PRO/PRO genotype may be associated with initial central visual field defects in caucasians with primary open angle glaucoma.

Authors:  Janey L Wiggs; Alex W Hewitt; Bao Jian Fan; Dan Yi Wang; Dayse R Figueiredo Sena; Colm O'Brien; Anthony Realini; Jamie E Craig; David P Dimasi; David A Mackey; Jonathan L Haines; Louis R Pasquale
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

7.  Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma.

Authors:  Xiaoxue Xie; Hui Wang; Hekun Jin; Shuyu Ouyang; Jumei Zhou; Jun Hu; Xuping Xi; Junming Luo; Yingying Zhang; Bingqiang Hu
Journal:  Radiat Oncol       Date:  2013-05-11       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.